Vinmec Makes Varian Image-Guided and RapidArc Treatments Available to Cancer Patients in Vietnam

Food and Healthcare Press Releases Wednesday April 22, 2015 08:49
HANOI, Vietnam--22 Apr--PRNewswire/InfoQuest
Vinmec International Hospital here in Hanoi has commenced offering cancer patients advanced radiotherapy with a new Clinac(R) iX medical linear accelerator from Varian Medical Systems (NYSE: VAR).

The Clinac iX system enables the hospital to deliver intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), and some forms of stereotactic body radiotherapy (SBRT). Equipped with Varian's RapidArc(R) technology, the new accelerator can deliver treatments quickly so that more patients have access to these modern treatment techniques. The clinic is also using Varian's Eclipse(TM) treatment planning software to target tumors precisely while protecting surrounding healthy tissue. Early treatments at the hospital are focusing on thoracic cancers, gynecological cancers, head & neck cancers, prostate cancers, and localized lymphoma.

"It is very important that cancer patients in this country can benefit from the most modern forms of radiotherapy," said radiation oncologist Dr. Doan Trung Hiep, MD, MSc. "This excellent device has an advanced image guided radiotherapy system that makes it possible to deliver fast, targeted treatments to tumors even as they move and change over time. It also means we can expand the range of tumors we can target with our first stereotactic radiosurgery treatments."

Vinmec International Hospital is the first radiotherapy center established by the Vinmec International Hospital Joint Stock Company, aimed at helping to bridge the capacity gap in the country. There are more than 90 million people in Vietnam but fewer than 30 linear accelerators are installed in the country's hospitals. Vinmec is planning to establish up to ten private radiotherapy centers by 2020.

"We are committed to establishing a world-class radiation oncology capability in Vietnam with more modern equipment, trained clinicians and a radiotherapy education program," said Dr. Doan Trung Hiep. "Vinmec is proud to be working with Varian to develop this treatment capability for our patients."

Michael Sandhu, Varian's VP global market development, said, "We are honored to be working with Vinmec to offer advanced treatment technology for the benefit of cancer patients across Vietnam. Through initiatives such as this and through our educational programs such as 'Access to Care', Varian is working to expand access to modern radiotherapy globally." Varian's first Access to Care program was launched in Vietnam earlier this year, with 15 students combining internships at local hospitals with sessions at a specially-equipped training center in Hanoi.

Editorial contact:
Neil Madle, Varian Medical Systems, +44 7786 526068
About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 6,800 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit or follow us on Twitter .

Latest Press Release

Michel Orsinger Assumes Role as Chairman of Limacorporate#s Advisory Board

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in...

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the...

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Ascensia Diabetes Care Highlights the Support That Families Provide for People With Diabetes To Mark World Diabetes Day 2018

Today, Ascensia Diabetes Care, a global leading diabetes care company, launched their campaign for World Diabetes Day 2018 to celebrate the important role of families for people with diabetes. They are publishing 38 online artworks that tell the stories...

Related Topics